ELECTRONIC LETTER

Death in adults with Prader-Willi syndrome may be correlated with maternal uniparental disomy

A Smith, G Loughnan, K Steinbeck

J Med Genet 2003;40:e63(<http://www.jmedgenet.com/cgi/content/full/40/5/e63>)

Prader-Willi syndrome (PWS) is a disorder comprising severe neonatal hypotonia, hypogonadism, gross obesity, short stature, small hands and feet, mental handicap, a characteristic facial appearance (almond shaped eyes, thin downturned upper lip, and a narrow bitemporal diameter), nasal, inarticulate speech, and a particular personality profile.^{1,2} Prader-Willi syndrome has a biphasic course. Initially there is severe neonatal hypotonia, difficulty in feeding, and failure to thrive, usually persisting for 12 months. This is followed by weight gain, and if unchecked obesity is well developed by 6 years of age.^{1,2} The gain in weight is primarily attributable to a hypothalamic defect resulting in an insatiable appetite and hyperphagia,^{3,4} but a lowered metabolic rate and lack of exercise owing to continuing hypotonia contribute.⁵ The patients have a food obsession with a rather specific food related behavioural phenotype, which includes foraging for food, stealing food, and eating inedibles.^{1,3}

The clinical diagnosis of PWS can now be confirmed by accurate genetic testing. Methylation testing makes a definitive diagnosis in about 99% of patients, but will not define the genetic mechanism. Further simple DNA studies of the chromosome 15 (q11-q13) region will do this. These include fluorescence in situ hybridisation (FISH) to check for deletion and DNA polymorphisms for maternal uniparental disomy (UPD).⁶ A patient with a positive methylation result who is non-deleted and non-disomic has an imprinting defect (ID).⁷ The commonest genetic mechanism is paternal deletion of the

imprinted region (about 75% of patients), followed by UPD in 24% and about 1% have an ID for this region.^{6,7}

Adults with PWS are cared for in various ways throughout the community.^{5,8,9} Cohorts of adults with PWS seen at clinics in the past found that morbid obesity was usual.^{3-5,8} A recent study from the United Kingdom has confirmed a continuing high morbidity, despite better early diagnosis, knowledge, and management of PWS.¹⁰ This morbidity among adults is largely the result of complications associated with obesity, such as diabetes (mainly type 2), sleep apnoea, respiratory arrest, peripheral circulatory stagnation, slow healing of skin lesions, and osteoporosis,^{1-5,10,11} but the hypotonia, which continues into adult life, contributes (for example, scoliosis, kyphosis, lack of exercise). Psychological problems are a cause of major concern to families, reported in 5%–15% of adult patients, and range from obsessive skin picking to overt cyclical psychosis.¹²⁻¹⁴ Hypothalamic insufficiency contributes to hypogonadism, temperature instability, low activity levels, and low metabolic rate, further affecting morbidity.¹¹ A mortality rate for PWS has not been established by prospective studies. A retrospective prevalence population study in the United Kingdom estimated a mean mortality rate of 3% a year across all ages and 7% a year in those over 30 years of age.⁹

We present our findings in a cohort of adults with PWS consistently attending a multidisciplinary PWS clinic over the 10 year period 1991–2001. Our review was conducted to assess outcome data for adult patients and to look for possible future interventions which might improve clinical management.

Key points

- Prader-Willi syndrome (PWS) in adulthood is difficult to manage. We present our findings in 36 adults, seen at a multidisciplinary PWS clinic in a major Sydney teaching hospital over a 10 year period.
- There were 18 women and 18 men; mean age on admission was 26 (range 14–48) years. All patients had PWS established by DNA testing. On admission, the BMI of the patients with deletion was 41.2, the same as those with UPD (42.6). Morbidity was high; all had a history of sleep apnoea, 19% had diabetes, and 28% had episodes of psychiatric illness. There were 10 deaths (28%) during the time of the study, six women, four men, mean age at death 33.2 (range 20–49) years.
- In 60%, the cause of death was considered to be circulatory in origin, either strokes, coronary occlusion, or heart failure. There was no significant difference in obesity between those who died and those still alive, and there were no predictive variables for premature death. More than the expected numbers of patients who died had UPD.
- Our findings suggest that a thorough heart survey is required in the long term management of PWS.

PATIENTS AND METHODS

A multidisciplinary medical clinic for adults and adolescents with PWS at the Royal Prince Alfred Hospital, Sydney receives referrals from clinicians, carers, and parents throughout the State of New South Wales. The service, staffed by an endocrinologist, dietician, and physiotherapist, has remained constant for 10 years since its inception in 1991. A social worker joined the team in 2001. Consultation is available for sleep disorders, and dermatological, psychological, psychiatric, and genetic indications, if required. General practitioners and other specialists are often peripherally involved. The clinics are held bimonthly.

At the clinic, patients initially attended an individual consultation in which history and physical examination were obtained and other disorders, for example, diabetes and sleep apnoea, were ascertained. A blood specimen was taken for biochemistry, haematology, and genetic testing. Genetic testing starts with routine cytogenetics, followed by a DNA based test.^{15,16} Measurements of height and weight were recorded and body mass index (BMI) calculated.

Abbreviations: BMI, body mass index; FISH, fluorescence in situ hybridisation; ID, imprinting defect; PWS, Prader-Willi syndrome; UPD, uniparental disomy

Table 1 Characteristics of patients still living

ID	Age oa	Wt oa	BMI oa	Genetic mechanism	Diabetes	Psych illness	Smoking	Years of FU	Alive age	Last wt
F1	14	66.7	28.9	Del				5	19	105.4
F2	15	62.2	32.7	Del			y	9	24	114.7
F3	15	79.1	40.4	Del				4	19	79.1
F4	23	62.2	33.6	Del		y		4	27	61
F5	25	142	79.2	Del			y	5	30	142.2
F6	26	79.5	38.3	Del	y		y	9.5	36	65.9
F7	27	66	34.2	UPD				7	34	74.7
F8	34	102	44.7	UPD		y	y	10	44	98.1
F9	36	83.6	38.7	Del				3	39	76
F10	38	68.3	37.5	Unknown				1.5	39	66.4
F11a	39	74.3	35.3	ID		y		5.5	44	72.1
F12	48	90.8	46.7	Unknown				2	50	90.8
M1	15	114	50.8	Del		y		3	18	141.4
M2	16	92.3	38.9	Del				1.5	18	99
M3	16	97.8	42.1	Del		y		2	18	111.5
M4	17	83.7	40.5	UPD				1	18	83.7
M5	17	80.8	28.3	Del			y	1	18	79.9
M6	21	87.9	30.1	Del	y		y	7	28	147.7
M7	22	130	57.6	Unknown				6	28	119.6
M8	23	96.1	36.6	Del	y			3	26	95.3
M9	23	73.6	30.2	Del				7	30	102.2
M10	25	87	32	Del		y		9	35	83.4
M11	27	120	47.9	UPD	y		y	6	33	123.5
M12	29	152	61.7	Del				2	31	144.5
M13	30	124	56	Unknown				0.5	30.5	121.7
M14	37	110	45.8	Del				3	40	103.7

F, female; M, male; oa, on admission; wt, weight; psych, psychiatric; FU, follow up; age is in years; weight is in kg; del, deletion; ID, imprinting defect; UPD, maternal uniparental disomy; y, yes; * insulin dependent; under last wt, weight in bold is gain since admission, weight in italics is loss since admission. Patient ID F11a is in Builing *et al.*⁷

All patients had standard clinical cardiovascular assessment for blood pressure and auscultation. Food intake, exercise output, and living conditions were assessed. Strict management guidelines included a restrictive diet (1000–1200 kcal/day) and regular daily exercise, to be recorded on a standard form. Very strong emphasis was placed on regular daily exercise.

At subsequent PWS clinics, each patient was reviewed individually, and then all attended a one hour group session. This has an educational component with discussion of appropriate food intake, exercise, body awareness, hygiene, and self care. Physical activity and socialisation within the group were encouraged. Those patients who have achieved weight loss since the last clinic received incentive certificates of merit awards. Parents and other carers met separately to discuss management strategies.

The patients were well known to the clinic staff and telephone consultations between patients and carers and clinic staff also occurred.

All clinic patients who were older than 18 at the end of the 10 year study period were included in this report.

RESULTS

From February 1991 to the end of 2001, 36 adult patients with PWS have attended the clinic, with a total of 507 attendances. The number of patients seen at each clinic averaged around 12. The three longest standing patients have attended on 54, 53, and 49 occasions, whereas four have attended only once. There were 18 female and 18 male patients. The mean age of patients on admission was 26 years (range 14–48 years).

The height, weight, BMI on admission, and other variables are shown in tables 1 and 2. There were no significant sex differences in age, weight, or BMI. Female patients were shorter than male patients ($p=0.002$). One patient (F8) had been on an appetite suppressant at the time of admission. No patient had been on growth hormone at any time. No patient had another unrelated medical disorder.

All patients had PWS established by a DNA test. The mechanism was undetermined in five, that is, methylation was positive, FISH was non-deleted, but further work up was not done. It is likely that these patients had UPD, but they have been excluded from correlations based on genetic mechanisms. Of the remaining 31 patients, the mechanism was paternal deletion in 22 (71%) (10 female and 12 male patients), UPD in eight (26%) (four women and four men)^{15–16} and an imprinting defect in one women.⁷ On admission, the mean age of the patients with deletion was 23.6 years (range 15–44) and with UPD it was 26.75 years (range 18–34) ($p=0.5$).

On admission, the mean BMI for those with deletion was 36.5 m²/kg (range 29–52.2) and for those with UPD it was 43.8 m²/kg (range 35–56.5) ($p=0.03$). Most patients (21/36 (58%)) were in obesity class III (BMI ≥ 40) whereas 10 (28%) were in obesity class II (BMI 35–39.9), that is, 31/36 (86%) were significantly obese. One patient was in obesity class I (BMI 30–34.9) and four patients were pre-obese (BMI 25–29.9). Diabetes was present in seven patients (18%); 4/7 had deletion (57%) and 3/7 had UPD (43%) ($p=0.5$). Skin picking was common, manifest in 30/39 patients (15/19 female (79%) and 15/20 male patients (75%)). Lymphoedema was present in 14/36 (39%) (in 10/18 female (55.5%) and 4/18 male patients (22%)). All patients gave a history of sleep apnoea at some time; sleep apnoea was present in 4/4 tested in the sleep laboratory. Eleven patients (30.5%) were known smokers but it was not possible to obtain an accurate figure for the number of cigarettes smoked each day. At least one episode of psychiatric illness, necessitating consultation and treatment by a psychiatrist, occurred in 10 patients (28%). Of these, one had an imprinting defect,⁷ five were deleted, and four had UPD. One patient (F8) had osteoporosis and had hip replacement surgery at the age of 32. No patient was capable of independent living, but the level of care and supervision varied. Three patients lived in a dedicated PWS home, 15 patients lived in the family home with one or both parents (15/36 (42%)), and

Table 2 Characteristics of patients who died

ID	Age oa	Wt oa	BMI oa	Genetic mechanism	Diabetes	Psych illness	Smoking	Years of FU	Age at death	Last wt	Cause of death
F13	17	101	42.6	Del				0	22	101	Not determined, sudden collapse, died in hospital
F14	26	129	52.2	Del		y		1	27	141	Pneumonia, died at home
F15	30	86	42.7	UPD	y		y	1	32	82	Profound hypoglycaemia of sudden onset, died in nursing home
F16	32	122	51.5	Unknown				2	39	133	Coronary occlusion, sudden, died at home
F17b	33	85	41.5	UPD	y*	y		8	42	73	Several small strokes over a month, died in nursing home after a massive stroke
F18	38	88	38.9	Del			y	1	40	96	Pulmonary embolus, sudden death in group home
M15c	18	91	32.7	UPD		y		2	20	130	Cardiac and respiratory failure, deteriorating over 3 months, died at home
M16	19	81	34.1	Del	y			3	24	73	Not determined, sudden collapse with unconsciousness, died in hospital
M17	28	102	45.3	UPD		y	y	9	37	66	Postoperative (complicated rectal surgery) cardiorespiratory failure, in hospital
M18	44	106	45.1	Del				5	49	80	Congestive cardiac failure following respiratory illness, died in hospital

For abbreviations see table 1. Patient ID; F17b is in Smith and Noel¹⁶; M15c is in Lamb and Johnson.¹⁷

the remaining 18 patients (50%) lived in hostel accommodation or other supervised non-PWS group home. All the patients had periods of living at home interspersed with supervised care during this 10 year period and most patients living away from home visited family at weekends.

Clinical progress over the 10 years fluctuated for all patients, with periods of weight loss interspersed with periods of weight gain. One patient (F8) (table 1) with UPD showed a 30 kg weight fluctuation several times over a six year period, depending on living conditions, with the least weight recorded (72.3 kg) when living in a restricted environment. Patient F2, with a weight of 62.2 kg on admission at age 15 years, weighed 129 kg at the age of 20. Exercise charts showed that many patients were able to maintain a regular routine of, for example, walking, but strict supervision and encouragement were needed to achieve this.

Deaths

Ten patients have died, with a mean age at death of 33.2 years (range 20–49 years). In comparing those who died with those still alive (tables 1 and 2), there were no significant differences between the two groups for sex (six female patients, 33% died; four male patients, 22% died), the frequency of diabetes, weight gain or weight loss, exercise compliance, obesity class on admission, living conditions, smoking, or psychiatric illness. Among those extremely overweight on admission (BMI over 50) 4/26 are alive (15%) compared with 2/10 (20%) who have died ($p=0.5$). Three of the patients who died (30%) had been followed up for five years or more compared with 12/26 still alive (46%) ($p=0.05$); the follow up time for those who died was less (3.2 years) than those still alive (4.5 years). None of the clinical variables followed predicted those patients at risk of death or separated them from those still alive.

There was a significant difference when comparing the genetic mechanisms between the two groups, 5/9 (56%) with deletion died compared with 17/22 with deletion still alive (77%); 4/9 (44%) with UPD died compared with 4/22 (18%) with UPD still alive ($p<0.05$). The numbers in each cohort are small; if we assumed that those with unknown mechanisms had UPD (which is most likely), then the trend is maintained, with 5/10 with UPD among those who died (50%) compared with 8/26 among those alive (31%) ($p<0.05$). Thus UPD seems to be an independent risk factor for death in the young adult age range in PWS.

The cause of death is shown in table 2. Overall, the cause of death was cardiopulmonary disease in 6/10 patients, 7/10 patients died unexpectedly, and in five patients death was sudden. In only three patients was the illness before death

prolonged, patients F14, F17, and M15. In patients F13 and M16, the cause of death was not precisely determined. Postmortem examinations were performed on two patients, M16 (non-contributory findings) and M17 (he had rectal bleeding, which may have resulted from skin picking; postmortem showed a singular rectal ulcer with rectal prolapse and confirmed cardiorespiratory disease).

DISCUSSION

The patients in our study form a unique source of information on the natural history of PWS established by DNA testing, managed optimally in an informed state of the art clinic over a 10 year period. Other sources of natural history data, from case reports, reviews of clinic patients, reviews of patients in institutions, or population studies,^{3–5,9} have shown a high morbidity among adults with PWS, but the care has varied considerably and mostly a genetic diagnosis was not made. We confirm here the continuing high morbidity, even with consistent supportive optimal management.

Although it is difficult to consider any death in a group of patients with a known pre-morbid disease as totally unexpected, death may still be considered as unpredictable at the time it occurred, and this applied to most patients with PWS followed up at our clinic. Gross obesity is known to have serious complications affecting the cardiovascular and respiratory systems,⁴ which was the cause of death in most of our patients. The age of onset of coronary artery disease in PWS is not known but there is a report of severe disease, detected by imaging, already present in a 26 year old patient.¹⁷ Our data also point to early onset coronary artery disease in PWS.

Two patients had achieved significant weight loss, all were doing some exercise, and there were no additional diseases unrelated to obesity comorbidity among these patients, which could have compromised health further.¹⁸ One patient (M17), with rectal bleeding,¹⁹ had lost significant weight, had psychiatric illness, and smoked. Severe respiratory problems seem to be a cause of sudden unexpected death in infants and young children with PWS.^{20,21} In view of our findings, it is our intention to alter clinical practice to include electrocardiography and echocardiography on all patients at entry to the clinic and at defined intervals thereafter.

Although the numbers are small, a factor among the deaths seen in our study has been the effect of genotype. The patients with UPD overall were not heavier than the deleted patients when first seen, and followed a similar path of fluctuating control over the time period, but nevertheless were more likely to die. The search for clinical differences between those with deletion and those with UPD has not yielded consistent findings (apart from hypopigmentation in deletion patients),²² but

studies of psychotic disease in adults have also shown more UPD than expected.¹⁴ A hypothesis to explain these findings is that another gene(s) on chromosome 15 is maternally imprinted and when no paternal copy is present leads to deleterious effects on the function of specific brain and heart cells. Previous reports of adults with PWS who have died have not included genetic mechanisms.^{3-5 9 23}

Complications associated with obesity, including cardiopulmonary disease, are considered to be the main risk factors associated with morbidity and mortality in adults with PWS.¹¹ Other factors also contribute, such as hypothermia,⁴ decreased pain sensation,¹ sleep apnoea, diabetic complications, and obsessive behaviour. It has been shown that patients with PWS can lose weight in the short term on medication,²⁴ but no studies of long term weight reduction have appeared. No other study has followed up a cohort of patients for a long period, as we have done, and to date it has not been shown that improved weight control lengthens life in PWS. Long term weight reduction is a major goal of PWS management, but in our cohort consistent weight reduction was difficult to achieve. Strict supervision in the living environment seems to be of major benefit,^{5 8} accompanied by positive encouragement and awards.

ACKNOWLEDGEMENTS

We appreciate the support of Professor Ian Caterson, Head, Human Nutrition Unit, University of Sydney; Professor R Trent, Head of Department of Molecular Biology and Clinical Genetics, Royal Prince Alfred Hospital, Sydney; Lisa Robson, Dr Tina Buchholz, Department of Cytogenetics, and Dr Bruce Bennetts and Julianne Jackson, Department of Molecular Genetics, Children's Hospital at Westmead, Sydney, for the FISH and methylation results.

Authors' affiliations

A Smith, Department of Cytogenetics, New Children's Hospital, Westmead, Sydney, Australia
G Loughnan, K Steinbeck, Obesity and Metabolism Department, Royal Prince Alfred Hospital, Sydney, Australia
K Steinbeck, University of Sydney, Australia

Correspondence to: Dr A Smith, Department of Cytogenetics, Children's Hospital at Westmead, Locked Bag 4001, Westmead, NSW 2145, Australia; ellies@chw.edu.au

REFERENCES

- 1 **Holm VA**, Cassidy SB, Butler MG, Hanchett JM, Greenswag LR, Whitman BY, Greenberg F. Prader-Willi syndrome: consensus diagnostic criteria. *Pediatrics* 1993;**91**:398-402.
- 2 **Gunay-Aygun M**, Schwartz S, Heeger S, O'Riordan MA, Cassidy SB. The changing purpose of Prader-Willi syndrome clinical diagnostic criteria and proposed revised criteria. *Pediatrics* 2001;**108**:5/e92.
- 3 **Laurence BM**, Brito A, Wilkinson J. Prader-Willi syndrome after age 15 years. *Arch Dis Child* 1981;**56**:181-6.

- 4 **Bray GA**, Dahms WT, Swerdloff RS, Fiser RH, Atkinson RL, Carrel RE. The Prader-Willi syndrome: a study of 40 patients and a review of the literature. *Medicine* 1982;**62**:59-80.
- 5 **Greenswag L**. Adults with Prader-Willi syndrome: a survey of 232 cases. *Dev Med Child Neurol* 1987;**29**:145-152.
- 6 American Society of Human Genetics/American College of Medical Genetics Test and Technology Transfer Committee. Diagnostic testing for Prader-Willi and Angelman syndromes: report of the ASHG/ACMG test and technology transfer committee. *Am J Hum Genet* 1996;**58**:1085-8.
- 7 **Buiting K**, Dittich B, Gross S, Lich C, Farber C, Buchholz T, Smith E, Reis A, Burger J, Nothen M, Barthwite U, Janssen B, Abeliovich D, Lerner I, Schrander-Stumpel C, Smeets H, Meinecke P, Malcolm S, Gardner A, Lalande M, Nicholls R, Tommerup N, Matthijs G, Kokkonen H, Hilbert P, van Maldergem L, Glover G, Carbonell P, Willems P, Gillissen-Kaesbach G, Horsthemke B. Sporadic imprinting defects in Prader-Willi syndrome and Angelman syndrome: implications for imprint switching, genetic counselling and prenatal diagnosis. *Am J Hum Genet* 1998;**63**:170-80.
- 8 **Kaufman H**, Overton G, Leggott J, Clericuzio C. Prader-Willi syndrome: effect of group home placement on obese patients with diabetes. *South Med J* 1995;**88**:182-4.
- 9 **Whittington JE**, Holland AJ, Webb T, Butler J, Clarke D, Boer H. Population prevalence and estimated birth incidence and mortality rate for people with Prader-Willi syndrome in one UK health region. *J Med Genet* 2001;**38**:792-8.
- 10 **Butler JV**, Whittington JE, Holland AJ, Boer H, Clarke D, Webb T. Prevalence of, and risk for, physical ill health in people with Prader-Willi syndrome: a population based study. *Dev Med Child Neurol* 2002;**44**:248-55.
- 11 **Smith A**. The disability associated with Prader-Willi syndrome. *Australian Disability Rev* 1996;**4**:29-35.
- 12 **Einfeld SL**, Smith A, Durvasula S, Florio T, Tonge BJ. Behavior and emotional disturbance in Prader-Willi syndrome. *Am J Med Genet* 1999;**82**:123-7.
- 13 **Clarke DJ**. Prader-Willi syndrome and psychoses. *Br J Psychiatry* 1993;**163**:680-4.
- 14 **Boer H**, Holland A, Whittington J, Butler J, Webb T, Clarke D. Psychotic illness in people with Prader-Willi syndrome due to chromosome 15 maternal uniparental disomy. *Lancet* 2002;**359**:135-6.
- 15 **Smith A**, den Dulk G, Lipson A, Suter M. Classical Prader-Willi syndrome with trisomy 15 (pter→q12) plus de novo variant 15p11. *Ann Genet* 1989;**32**:39-42.
- 16 **Smith A**, Noel M. A girl with the Prader-Willi syndrome and Robertsonian translocation 45,XX,t(14;15)(p11;q11) which was present in three normal family members. *Hum Genet* 1980;**55**:271-3.
- 17 **Lamb AS**, Johnson WM. Premature coronary artery atherosclerosis in a patient with Prader-Willi syndrome. *Am J Med Genet* 1987;**28**:873-80.
- 18 **Robson WL**, Leung AK. Membranoproliferative glomerulonephritis in a child with Prader-Willi syndrome. *Am J Med Genet* 1992;**43**:858-9.
- 19 **Bhargava SA**, Putnam PE, Kocoshis SA, Rowe M, Hanchett JM. Rectal bleeding in Prader-Willi syndrome. *Pediatrics* 1996;**97**:265-7.
- 20 **Schrander-Stumpel C**, Sijstermans H, Curfs L, Frys JP. Sudden death in children with Prader-Willi syndrome: a call for collaboration. *Genet Couns* 1998;**9**:231-2.
- 21 **Reeve A**, Norman A, Sinclair P, Whittington-Smith R, Hamey Y, Donnai D, Read A. True telomeric translocation in a baby with the Prader-Willi phenotype. *Am J Med Genet* 1993;**47**:1-6.
- 22 **Robinson WP**, Bottani A, Yagang X, Balakrishnan J, Binkert F, Machler M, Prader A, Schinzel A. Molecular, cytogenetic, and clinical investigations of Prader-Willi syndrome patients. *Am J Hum Genet* 1991;**49**:1219-34.
- 23 **Carpenter PK**. Prader-Willi syndrome in old age. *J Intellect Disabil Res* 1994;**38**:529-31.
- 24 **Selikowitz M**, Sunman J, Pendergast A, Wright S. Fenfluramine in Prader-Willi syndrome: a double blind, placebo controlled trial. *Arch Dis Child* 1990;**65**:112-14.